Wuxi Biologics

71 articles with Wuxi Biologics

• WuXi Biologics Successfully Completed First FDA Routine GMP Inspection

  4/17/2019

  FDA typically conducts this inspection every two years upon product approval.

• I-Mab Biopharma and WuXi Biologics Announce Long-term Strategic Manufacturing Partnership for Five Clinical and One Commercial Programs

  4/16/2019

  I-Mab Biopharma and WuXi Biologics jointly announce today that the two companies have entered into a long-term strategic partnership on biologics process development, clinical and commercial manufacturing of I-Mab's highly innovative pipelines.

• WuXi Biologics and NBE-Therapeutics Announce Comprehensive ADC Development and Manufacturing Partnership

  4/10/2019

  NBE-Therapeutics develops next-generation iADC products with the aim to improve the outcome for cancer patients, as it continues to develop iADCs based on its proprietary technology platforms.

• WuXi Biologics Receives EMA GMP Certificates

  3/20/2019

  WuXi Biologics to be the first biologics company in China approved by both the U.S. FDA and EMA

• WuXi Biologics Continues to Deliver Record Results

  3/18/2019

  WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announces its audited annual results for the year ended December 31, 2018 today.

• WuXi Biologics Congratulates Amicus on Receiving FDA Breakthrough Therapy Designation for AT-GAA

  2/28/2019

  WuXi Biologics ("WuXi Bio") (Stock code: 2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, congratulates its strategic partner Amicus Therapeutics ("Amicus") (Nasdaq: FOLD) on receiving FDA Breakthrough Therapy Designation for AT-GAA (

• ABL Bio Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Novel Immune Check Point Bispecifics for $220 Million

  2/26/2019

  WuXi Biologics will receive an upfront payment as well as development, regulatory and commercial milestone payments of about $220 million, and will be entitled to royalties based on global sales of these programs.

• WuXi Biologics and Amicus Sign Exclusive Manufacturing Partnership

  2/11/2019

  WuXi Biologics ("WuXi Bio") (2269.HK), development and manufacturing, and Amicus Therapeutics ("Amicus") (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing and delivering high-quality medicines for people living with rare metabolic diseases, announced that the companies have entered into an exclusive commercial manufacturing partnership for Amicus' Pompe biologic ATB200.

• CANbridge Pharmaceuticals and WuXi Biologics Expand Rare Disease Therapeutics Partnership

  1/8/2019

  CANbridge Pharmaceuticals Inc. and WuXi Biologics jointly announced an expansion of their rare disease partnership to enable CANbridge to discover, develop and commercialize four additional drug candidates

• AC Immune and WuXi Biologics to Establish an Exclusive Strategic Partnership

  12/19/2018

  AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases and WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced the first steps of an exclusive strategic collaboration that covers biologics discovery, development and manufacturing.

• 

  WuXi Biologics and Oxford BioTherapeutics Expand Partnership With 5 More Antibody Compounds

  12/11/2018

  WuXi Biologics, a Shanghai, China-based contract research organization focused on biologics, announced it was expanding its existing collaboration and licensing deals with UK-based Oxford BioTherapeutics (OBT).

• WuXi Biologics Achieves Breakthrough Titer of 51g/L in Cell Culture Productivity

  12/11/2018

  WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that it has achieved a breakthrough in cell culture productivity for an Fc-fusion protein.

• Oxford BioTherapeutics Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Five Bispecific Antibody Programs for up to $450 Million

  12/11/2018

  WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing and Oxford BioTherapeutics Ltd.

• WuXi Biologics Announced Exclusive Discovery Research with Brii Biosciences for Novel Bispecific Antibody Immunotherapeutics

  12/10/2018

  WuXi Biologics announced today a strategic collaboration with Brii Biosciences

• 

  WuXi AppTec to Expand Facilities and Hire in San Diego

  12/10/2018

  At its San Diego site, the company plans to establish a center of excellence in screening, discovery biology, pharmacology, and small molecule process R&D, which will also include Phase I GMP manufacturing.

• WuXi Biologics Wins SCRIP Award for "Best Company in an Emerging Market"

  12/6/2018

  WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company that offers end-to-end solutions for biologics discovery, development and manufacturing, today announced that it has won the SCRIP Award in the category of "Best Company in an Emerging Market".

• WuXi Biologics and ABL Bio Enter an Exclusive Development and Clinical Manufacturing Partnership for Multiple Bispecific Antibodies

  11/28/2018

  WuXi Biologics (2269.HK, WuXi Bio), and ABL Bio Corporation (ABL Bio), today announced that the companies have entered into an exclusive development and clinical manufacturing partnership for up to 8 antibody therapeutics including ABL Bio’s biologics pipelines and collaboration programs between ABL Bio and I-Mab Biopharma (I-Mab).

• WuXi Biologics’ Chief Executive Officer Dr. Chris Chen to Serve on Board of Directors at ISPE and Delivered Keynote Speech at 2018 Annual Meeting

  11/7/2018

  Wuxi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced Dr. Chris Chen, Chief Executive Officer of WuXi Biologics, has been appointed by International Society for Pharmaceutical Engineering (ISPE) to serve on the International Board of Directors for a two-year term.

• WuXi Biologics Commenced Construction of 48,000L Biologics Commercial Manufacturing Center in Shijiazhuang

  10/31/2018

  The new Biologics Center will be one of the largest in northern China

• CANbridge Pharmaceutical Inc. and WuXi Biologics Enter into Strategic Partnership for Rare Disease Therapeutics

  10/23/2018

  CANbridge Plans to Submit First Rare Disease IND in China in 2019